logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN

Avantect

A pioneering test for the early detection and early diagnosis of pancreatic cancer

A pioneering test for the early detection and early diagnosis of pancreatic cancer

Avantect is a liquid biopsy gene test that detects genomic and epigenomic profiles in free circulating tumor DNA (cfDNA) associated with pancreatic cancer. Using this method we can detect pancreatic cancer faster than other methods, managing to detect the cancer at an early stage.


Identifying patients at high risk for pancreatic cancer

Widespread screening for pancreatic cancer is performed in specialized centers and is usually not feasible due to the lack of effective and affordable diagnostic tests.

  • Pancreatic cancer becomes more common with increasing age, with over 90% of cases diagnosed in people over the age of 50
  • In about 90% of cases, pancreatic cancer is sporadic, with the remaining 10% having a genetic origin. 

 

Prioritizing a significant high-risk population


While diabetes has long been recognized as a risk factor for pancreatic cancer, there is new evidence of a critical relationship between pancreatic cancer and newly diagnosed (<3 years) type 2 diabetes in patients aged 50 years and older.
Recent studies on the pathogenesis of pancreatic cancer suggest that although long-standing diabetes (>3 years) increases the risk and may play a causative role, new-onset diabetes may actually be a consequence of pancreatic cancer. (1% of patients with new-onset type 2 diabetes over the age of 50 will be diagnosed with pancreatic cancer in the next 3 years.)

 

Screening people with a family history of pancreatic cancer


Based on international guidelines, screening for pancreatic cancer is recommended in:

  • Carriers of STK11, CDKN2A mutations regardless of family history.
  • Carriers of mutations (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM,    PALB2, TP53), when there is at least one 1st or 2nd degree relative with  pancreatic cancer.
  • Patients with hereditary pancreatitis (mutations in PRSS1, SPINK1 genes)
  • Patients with chronic pancreatitis (20 years after initial diagnosis)

Optimized performance in high-risk patients

The Avantect test has been validated in patients at high risk of developing pancreatic cancer, including those aged 50 years and older with newly (<3 years old) diagnosed type 2 diabetes.

The test performance has an overall sensitivity of 66.7% and a specificity of 96.9%.

 

 

 

 

 

Change cookies consent Revoke cookies consent